▼ -55.76% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Eidos Therapeutics in the last 3 months. The average price target is $54.07, with a high forecast of $73.26 and a low forecast of $34.00. The average price target represents a -55.76% upside from the last price of $122.21.
The current consensus among 9 polled investment analysts is to hold stock in Eidos Therapeutics. This Hold consensus rating has held steady for over two years.
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.